HALO RSI Chart
Last 7 days
3.7%
Last 30 days
17.7%
Last 90 days
23.9%
Trailing 12 Months
34.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 863.0M | 0 | 0 | 0 |
2023 | 705.0M | 773.7M | 780.7M | 829.3M |
2022 | 471.6M | 487.5M | 580.6M | 660.1M |
2021 | 331.3M | 412.5M | 463.0M | 443.3M |
2020 | 164.4M | 180.5M | 199.6M | 267.6M |
2019 | 177.9M | 181.9M | 202.6M | 196.0M |
2018 | 317.9M | 319.4M | 281.2M | 151.9M |
2017 | 133.8M | 134.2M | 166.1M | 316.6M |
2016 | 146.7M | 146.7M | 146.7M | 146.7M |
2015 | 105.9M | 120.8M | 138.1M | 146.7M |
2014 | 54.9M | 58.9M | 57.5M | 75.3M |
2013 | 46.7M | 53.4M | 64.1M | 54.8M |
2012 | 56.0M | 40.6M | 22.9M | 42.3M |
2011 | 17.7M | 37.7M | 57.2M | 56.1M |
2010 | 0 | 13.7M | 13.6M | 13.6M |
2009 | 0 | 0 | 0 | 13.7M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 25, 2024 | connaughton bernadette | acquired | - | - | 6,501 | - |
Apr 25, 2024 | duncan barbara gayle | acquired | - | - | 6,501 | - |
Apr 25, 2024 | henderson jeffrey william | acquired | - | - | 6,501 | - |
Apr 25, 2024 | matsui connie | acquired | - | - | 6,501 | - |
Apr 25, 2024 | posard matthew l. | acquired | - | - | 6,501 | - |
Apr 25, 2024 | miyashita akiko moni | acquired | - | - | 6,501 | - |
Apr 25, 2024 | krishnan mahesh | acquired | - | - | 6,501 | - |
Apr 17, 2024 | labarre michael j. | sold | -384,890 | 38.489 | -10,000 | svp, chief technical officer |
Apr 17, 2024 | labarre michael j. | acquired | 81,100 | 8.11 | 10,000 | svp, chief technical officer |
Apr 16, 2024 | labarre michael j. | acquired | 81,100 | 8.11 | 10,000 | svp, chief technical officer |
Which funds bought or sold HALO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CASTLEARK MANAGEMENT LLC | sold off | -100 | -4,283,440 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -64.21 | -2,237,700 | 1,328,960 | -% |
May 16, 2024 | 2Xideas AG | reduced | -5.27 | 856,619 | 20,969,000 | 2.57% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.03 | 232,388 | 5,366,060 | 0.01% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -36.57 | -1,779,510 | 4,115,720 | -% |
May 16, 2024 | COMERICA BANK | reduced | -2.67 | 224,502 | 3,376,760 | 0.01% |
May 16, 2024 | HANCOCK WHITNEY CORP | reduced | -7.48 | 3,976 | 220,894 | 0.01% |
May 16, 2024 | Colony Group, LLC | added | 14.48 | 767,000 | 3,716,000 | 0.03% |
May 16, 2024 | Virtus Investment Advisers, Inc. | reduced | -54.23 | -157,330 | 159,750 | 0.11% |
May 16, 2024 | Tidal Investments LLC | reduced | -31.63 | -103,362 | 314,212 | -% |
Unveiling Halozyme Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Halozyme Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Halozyme Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -14.8% | 196 | 230 | 216 | 221 | 162 | 181 | 209 | 152 | 117 | 102 | 116 | 136 | 89.00 | 122 | 65.00 | 55.00 | 25.00 | 54.00 | 46.00 | 39.00 | 57.00 |
Costs and Expenses | -22.2% | 100 | 129 | 128 | 127 | 108 | 107 | 126 | 118 | 42.00 | 45.00 | 40.00 | 43.00 | 38.00 | 44.00 | 25.00 | 26.00 | 29.00 | 86.00 | 71.00 | 53.00 | 54.00 |
S&GA Expenses | -6.6% | 35.00 | 38.00 | 35.00 | 39.00 | 37.00 | 38.00 | 34.00 | 57.00 | 14.00 | 14.00 | 13.00 | 12.00 | 11.00 | 10.00 | 12.00 | 11.00 | 13.00 | 24.00 | 18.00 | 17.00 | 18.00 |
R&D Expenses | -10.4% | 19.00 | 21.00 | 17.00 | 20.00 | 18.00 | 23.00 | 17.00 | 15.00 | 12.00 | 10.00 | 8.00 | 8.00 | 9.00 | 7.00 | 8.00 | 9.00 | 10.00 | 45.00 | 30.00 | 34.00 | 31.00 |
EBITDA Margin | 7.2% | 0.49* | 0.46* | 0.44* | 0.41* | 0.36* | 0.41* | 0.43* | 0.50* | 0.65* | 0.58* | 0.61* | 0.60* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -13.7% | 5.00 | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 8.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 2.00 | 3.00 | 3.00 |
Income Taxes | 21.5% | 19.00 | 16.00 | 20.00 | 18.00 | 13.00 | 13.00 | 12.00 | 7.00 | 14.00 | -11.96 | -142 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.06 | 0.00 | 0.00 | 0.00 |
Earnings Before Taxes | -5.1% | 96.00 | 101 | 102 | 93.00 | 52.00 | 71.00 | 74.00 | 30.00 | 74.00 | 55.00 | 74.00 | 92.00 | 28.00 | 73.00 | 36.00 | 26.00 | -6.09 | -34.46 | -25.00 | -14.61 | 2.00 |
EBT Margin | 8.2% | 0.45* | 0.42* | 0.41* | 0.37* | 0.32* | 0.38* | 0.40* | 0.48* | 0.63* | 0.56* | 0.58* | 0.56* | - | - | - | - | - | - | - | - | - |
Net Income | -10.0% | 77.00 | 85.00 | 82.00 | 75.00 | 40.00 | 58.00 | 62.00 | 23.00 | 60.00 | 67.00 | 217 | 91.00 | 28.00 | 73.00 | 36.00 | 26.00 | -6.10 | -34.40 | -25.01 | -14.62 | 2.00 |
Net Income Margin | 8.8% | 0.37* | 0.34* | 0.33* | 0.30* | 0.26* | 0.31* | 0.36* | 0.75* | 0.92* | 0.91* | 0.88* | 0.55* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 26.2% | 126 | 100 | 129 | 68.00 | 76.00 | 80.00 | 69.00 | 39.00 | 47.00 | 82.00 | 121 | 36.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 6.2% | 1,842 | 1,733 | 1,893 | 1,810 | 1,699 | 1,842 | 1,865 | 1,781 | 1,162 | 1,104 | 1,185 | 1,026 | 967 | 580 | 524 | 527 | 492 | 566 | 370 | 418 | 429 |
Current Assets | 17.0% | 874 | 746 | 879 | 766 | 615 | 739 | 653 | 542 | 989 | 926 | 1,017 | 1,000 | 942 | 555 | 499 | 500 | 468 | 543 | 342 | 392 | 409 |
Cash Equivalents | 39.1% | 165 | 118 | 274 | 221 | 96.00 | 234 | 148 | 91.00 | 118 | 119 | 492 | 447 | 500 | 148 | 66.00 | 134 | 105 | 121 | 60.00 | 68.00 | 61.00 |
Inventory | 32.1% | 169 | 128 | 129 | 132 | 108 | 100 | 103 | 98.00 | 48.00 | 54.00 | 56.00 | 59.00 | 58.00 | 61.00 | 58.00 | 48.00 | 41.00 | 29.00 | 36.00 | 44.00 | 31.00 |
Net PPE | 9.9% | 42.00 | 38.00 | - | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 11.00 | 10.00 | 11.00 | 12.00 | 11.00 | 15.00 | 15.00 | 15.00 |
Goodwill | 0% | 417 | 417 | 417 | 417 | 416 | 409 | 199 | 199 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 0.9% | 1,664 | 1,649 | 1,643 | 1,659 | 1,634 | 1,672 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Liabilities | 17.0% | 132 | 112 | 115 | 116 | 92.00 | 131 | 109 | 200 | 112 | 117 | 113 | 114 | 107 | 421 | 27.00 | 26.00 | 42.00 | 86.00 | 108 | 135 | 139 |
Long Term Debt | 0.1% | 1,501 | 1,499 | 1,498 | 1,496 | 1,494 | 1,493 | 1,491 | 1,147 | 788 | 787 | 786 | 786 | 785 | - | 394 | 390 | 387 | 383 | 9.00 | 14.00 | 19.00 |
LT Debt, Current | - | - | - | - | - | - | 13.00 | 13.00 | 99.00 | 90.00 | 89.00 | 89.00 | 89.00 | 89.00 | 397 | - | - | 3.00 | 20.00 | 55.00 | 71.00 | 87.00 |
LT Debt, Non Current | -100.0% | - | 1,499 | 1,498 | 1,496 | 1,494 | 1,493 | 1,491 | - | - | 787 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 112.2% | 178 | 84.00 | 249 | 151 | 66.00 | 170 | 97.00 | 293 | 260 | 197 | 282 | 120 | 68.00 | 151 | 99.00 | 106 | 58.00 | 92.00 | 245 | 260 | 260 |
Retained Earnings | 84.8% | 167 | 91.00 | 222 | 140 | 66.00 | 143 | 86.00 | 24.00 | 1.00 | -58.91 | -125 | -342 | -433 | -474 | -547 | -583 | -609 | -603 | -569 | -544 | -529 |
Additional Paid-In Capital | 389.6% | 12.00 | 2.00 | 26.00 | 12.00 | - | 27.00 | 13.00 | 271 | 262 | 256 | 407 | 462 | 501 | 625 | 646 | 688 | 668 | 695 | 814 | 804 | 789 |
Shares Outstanding | 0.3% | 127 | 127 | 132 | 132 | 132 | 135 | 137 | 138 | 138 | 141 | 142 | 140 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 3,500 | - | - | - | 5,100 | - | - | - | 5,600 | - | - | - | 2,900 | - | - | - | 2,500 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 26.5% | 129,427 | 102,354 | 132,411 | 66,842 | 86,964 | 82,453 | 69,635 | 40,225 | 47,797 | 82,516 | 121,739 | 36,889 | 58,296 | 50,920 | 6,084 | 3,294 | -4,844 | -26,625 | -29,588 | -24,786 | -4,424 |
Share Based Compensation | 2.2% | 9,874 | 9,664 | 9,368 | 9,622 | 7,966 | 7,223 | 6,797 | 5,635 | 4,742 | 5,126 | 5,399 | 5,372 | 4,923 | 4,196 | 4,220 | 4,257 | 4,531 | 7,229 | 8,239 | 9,833 | 9,475 |
Cashflow From Investing | -897.2% | -82,681 | -8,291 | -83,450 | 54,994 | -60,162 | -1,746 | -1,008 | -434,946 | -49,305 | -299,469 | -16,954 | -44,616 | -45,250 | 58,441 | -30,095 | 11,899 | 38,109 | -122,818 | 40,999 | 47,457 | 28,813 |
Cashflow From Financing | 99.8% | -489 | -249,920 | 4,101 | 2,446 | -164,614 | 6,329 | -12,400 | 367,818 | 624 | -156,011 | -60,068 | -44,757 | 338,701 | -27,399 | -43,854 | 13,593 | -48,624 | 210,420 | -19,250 | -16,225 | -21,730 |
Buy Backs | -100.0% | - | 252,300 | - | - | 150,083 | 1.00 | 200,001 | - | - | 160,321 | 64,716 | 48,842 | 76,179 | 38,896 | 58,902 | 1,996 | 51,574 | - | - | - | - |
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | ||
Total revenues | $ 195,879 | $ 162,143 |
Operating expenses | ||
Cost of sales | 28,329 | 35,170 |
Amortization of intangibles | 17,763 | 17,835 |
Research and development | 19,111 | 17,979 |
Selling, general and administrative | 35,134 | 37,357 |
Total operating expenses | 100,337 | 108,341 |
Operating income | 95,542 | 53,802 |
Other income (expense) | ||
Investment and other income, net | 4,993 | 2,979 |
Interest expense | (4,507) | (4,543) |
Net income before income taxes | 96,028 | 52,238 |
Income tax expense | 19,205 | 12,623 |
Net income | $ 76,823 | $ 39,615 |
Earnings per share | ||
Basic (USD per share) | $ 0.61 | $ 0.29 |
Diluted (USD per share) | $ 0.60 | $ 0.29 |
Weighted average common shares outstanding | ||
Basic (shares) | 126,941 | 135,027 |
Diluted (shares) | 128,887 | 137,900 |
Royalties | ||
Revenues | ||
Total revenues | $ 120,593 | $ 99,640 |
Product sales, net | ||
Revenues | ||
Total revenues | 58,583 | 60,794 |
Revenues under collaborative agreements | ||
Revenues | ||
Total revenues | $ 16,703 | $ 1,709 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 164,627 | $ 118,370 |
Marketable securities, available-for-sale | 298,824 | 217,630 |
Accounts receivable, net and contract assets | 195,902 | 234,210 |
Inventories, net | 168,541 | 127,601 |
Prepaid expenses and other current assets | 45,690 | 48,613 |
Total current assets | 873,584 | 746,424 |
Property and equipment, net | 78,071 | 74,944 |
Prepaid expenses and other assets | 17,319 | 17,816 |
Goodwill | 416,821 | 416,821 |
Intangible assets, net | 455,116 | 472,879 |
Deferred tax assets, net | 616 | 4,386 |
Total assets | 1,841,527 | 1,733,270 |
Current liabilities | ||
Accounts payable | 13,325 | 11,816 |
Accrued expenses | 118,314 | 100,678 |
Total current liabilities | 131,639 | 112,494 |
Long-term debt, net | 1,500,879 | 1,499,248 |
Other long-term liabilities | 31,201 | 37,720 |
Total liabilities | 1,663,719 | 1,649,462 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock - $0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 127 | 127 |
Additional paid-in capital | 11,794 | 2,409 |
Accumulated other comprehensive loss | (1,486) | (9,278) |
Retained earnings | 167,373 | 90,550 |
Total stockholders’ equity | 177,808 | 83,808 |
Total liabilities and stockholders’ equity | $ 1,841,527 | $ 1,733,270 |